Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter

Neuroscience

Volumn 164, Issue 3, 2009, Pages 1263-1273

  Pelegrini da Silva, A ^a   Rosa, E ^a   Guethe, L M ^a   Juliano, M A ^b   Prado, W A ^a   Martins, A R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antinociception; CGP 42,112A; divalinal angiotensin IV; Losartan; renin angiotensin system; tail flick and allodynia models

Indexed keywords

AMASTATIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN III; GLUTAMYL AMINOPEPTIDASE; LOSARTAN; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NOCICEPTION; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; RAT; TAIL FLICK TEST;

ANALGESICS; ANGIOTENSIN II; ANGIOTENSIN III; ANIMALS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; EFFERENT PATHWAYS; GLUTAMYL AMINOPEPTIDASE; LOSARTAN; MALE; MICROINJECTIONS; NEURAL INHIBITION; NOCICEPTORS; OLIGOPEPTIDES; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PEPTIDES; PERIAQUEDUCTAL GRAY; RATS; RATS, WISTAR; RECEPTORS, ANGIOTENSIN;

EID: 70350557035     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.09.004     Document Type: Article

References (70)

1. Abhold R.H., Sullivan M.J., Wright J.W., and Harding J.W. Binding, degradation and pressor activity of angiotensins II and III after aminopeptidase inhibition with amastatin and bestatin. J Pharmacol Exp Ther 242 (1987) 957-962
2. Almenoff J., and Orlowski M. Membrane-bound kidney neutral metalloendopeptidase: interaction with synthetic substrates, natural peptides, and inhibitors. Biochemistry 22 (1983) 590-599
3. Antunes-Rodrigues J., de Castro M., Elias L.L., Valenca M.M., and McCann S.M. Neuroendocrine control of body fluid metabolism. Physiol Rev 84 (2004) 169-208
4. Azami J., Llewelyn M.B., and Roberts M.H. An extra-fine assembly for intracerebral injection. J Physiol 303 (1980) 18P-19P
5. Azami J., Llewelyn M.B., and Roberts M.H. The contribution of nucleus reticularis paragigantocellularis and nucleus raphe magnus to the analgesia produced by systemically administered morphine, investigated with the microinjection technique. Pain 12 (1982) 229-246
6. Bader M., and Ganten D. Update on tissue renin-angiotensin systems. J Mol Med 86 (2008) 615-621
7. Behbehani M.M. Functional characteristics of the midbrain periaqueductal gray. Prog Neurobiol 46 (1995) 575-605
8. Bennett Jr. J.P., and Snyder S.H. Angiotensin II binding to mammalian brain membranes. J Biol Chem 251 (1976) 7423-7430
9. Bodineau L., Frugière A., Marc Y., Claperon C., and Lhorens-Cortes C. Aminopeptidase A inhibitors as centrally acting antihypertensive agents. Heart Fail Rev 13 (2008) 311-319
10. Brennan T.J., Vandermeulen E.P., and Gebhart G.F. Characterization of a rat model of incision pain. Pain 64 (1996) 493-501
11. Chan J.Y., Tsai H.F., Kuo T.B., and Chan S.H. Modulation by angiotensin III of nociception-related and arterial pressure-related neuronal responsiveness in the nucleus reticularis gigantocellularis of the rat. Regul Pept 50 (1994) 247-257
12. de Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
13. 3 receptor network after 20 years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol 560 (2007) 1-8
14. Fardin V., Oliveras J.L., and Besson J.M. A reinvestigation of the analgesic effects induced by stimulation of the periaqueductal gray matter in the rat. I. The production of behavioral side effects together with analgesia. Brain Res 306 (1984) 105-123
15. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., and Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension 30 (1997) 535-541
16. Ferrario C.M., and Iyer S.N. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept 78 (1998) 13-18
17. Fournie-Zaluski M.C., Fassot C., Valentin B., Djordjijevic D., Reaux-Le Goazigo A., Corvol P., Roques B.P., and Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci U S A 101 (2004) 7775-7780
18. Frederickson R.C.A., Burgis V., Harrel C.E., and Edwards J.D. Dual actions of substance P on nociception: possible role of endogenous opioids. Science 199 (1978) 1359-1362
19. Georgieva D., and Georgiev V. The role of angiotensin II and of its receptor subtypes in the acetic acid-induced abdominal constriction test. Pharmacol Biochem Behav 62 (1999) 229-232
20. Greene L.J., Spadaro A.C., Martins A.R., Perussi De Jesus W.D., and Camargo A.C. Brain endo-oligopeptidase B: a post-proline cleaving enzyme that inactivates angiotensin I and II. Hypertension 4 (1982) 178-184
21. Hamalainen M.M., Gebhart G.F., and Brennan T.J. Acute effect of an incision on mechanosensitive afferents in the plantar rat hindpaw. J Neurophysiol 87 (2002) 712-720
22. Harding J.W., Yoshida M.S., Dilts R.P., Woods T.M., and Wright J.W. Cerebroventricular and intravascular metabolism of [125I]angiotensins in rat. J Neurochem 46 (1986) 1292-1297
23. Haulica I., Neamtu C., Stratone A., Petrescu G., Branisteanu D., Rosca V., and Slatineanu S. Evidence for the involvement of cerebral renin-angiotensin system (RAS) in stress analgesia. Pain 27 (1986) 237-245
24. Hauser W., Johren O., and Saavedra J.M. Characterization and distribution of angiotensin II receptor subtypes in the mouse brain. Eur J Pharmacol 348 (1998) 101-114
25. Jensen T.S., and Yaksh T.L. Comparison of the antinociceptive effect of morphine and glutamate at coincidental sites in the periaqueductal gray and medial medulla in rats. Brain Res 476 (1989) 1-9
26. Krebs L.T., Kramar E.A., Hanesworth J.M., Sardinia M.F., Ball A.E., Wright J.W., and Harding J.W. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul Pep 67 (1996) 123-130
27. Lind R.W., Swanson L.W., and Ganten D. Organization of angiotensin II immunoreactive cells and fibers in the rat central nervous system: an immunohistochemical study. Neuroendocrinology 40 (1985) 2-24
28. Llorens-Cortes C., and Kordon C. Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems. J Neuroendocrinol 20 (2008) 279-289
29. Lowry O.H., Rosebrough N.J., Farr A.L., and Randal R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
30. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A., and Chai S.Y. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 35 (2003) 901-918
31. Mitsui T., Kakizaki H., Matsuura S., Tanaka H., Yoshioka M., and Koyanagi T. Chemical bladder irritation provokes c-fos expression in the midbrain periaqueductal gray matter of the rat. Brain Res 967 (2003) 81-88
32. Monhemius R., Green D.L., Roberts M.H., and Azami J. Periaqueductal gray mediated inhibition of responses to noxious stimulation is dynamically activated in a rat model of neuropathic pain. Neurosci Lett 298 (2001) 70-74
33. Moriguchi S., Shioda N., Han F., Yeh J.Z., Narahashi T., and Fukunaga K. Galantamine enhancement of long-term potentiation is mediated by calcium/calmodulin-dependent protein kinase II and protein kinase C activation. Hippocampus 19 (2009) 844-854
34. Palmieri F.E., Bausback H.H., and Ward P.E. Metabolism of vasoactive peptides by vascular endothelium and smooth muscle aminopeptidase M. Biochem Pharmacol 38 (1989) 173-180
35. Patchett A.A., Harris E., Tristram E.W., Wyvratt M.J., Wu M.T., Taub D., Peterson E.R., Ikeler T.J., ten Broeke J., Payne L.G., Ondeyka D.L., Thorsett E.D., Greenlee W.J., Lohr N.S., Hoffsommer R.D., Joshua H., Ruyle W.V., Rothrock J.W., Aster S.D., Maycock A.L., Robinson F.M., Hirschmann R., Sweet C.S., Ulm E.H., Gross D.M., Vassil T.C., and Stone C.A. A new class of angiotensin-converting enzyme inhibitors. Nature 288 (1980) 280-283
36. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, New York 46-49
37. Pelegrini-da-Silva A., Martins A.R., and Prado W.A. A new role for the renin-angiotensin system in the rat periaqueductal gray matter: angiotensin receptor-mediated modulation of nociception. Neuroscience 132 (2005) 453-463
38. Pelegrini-da-Silva A., Prado W.A., Juliano M.A., Wilk S., and Martins A.R. High-performance liquid chromatographic separation of renin-angiotensin system peptides and most of their metabolic fragments. J Chromatogr B Anal Technol Biomed Life Sci 780 (2002) 301-307
39. Prado W.A., Pelegrini-da-Silva A., and Martins A.R. Microinjection of renin-angiotensin system peptides in discrete sites within the rat periaqueductal gray matter elicits antinociception. Brain Res 972 (2003) 207-215
40. Raghavendra V., Chopra K., and Kulkarni S.K. Brain renin angiotensin system (RAS) in stress-induced analgesia and impaired retention. Peptides 20 (1999) 335-342
41. Reaux A., Fournie-Zaluski M.C., David C., Zini S., Roques B.P., Corvol P., and Llorens-Cortes C. PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Neuroendocrinology 69 (1999) 370-376
42. Reaux A., Fournie-Zaluski M.C., and Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 12 (2001) 157-162
43. Rees H., Prado W.A., Rawlings S., and Roberts M.H. The effects of intraperitoneal administration of antagonists and development of morphine tolerance on the antinociception induced by stimulating the anterior pretectal nucleus of the rat. Br J Pharmacol 92 (1987) 769-779
44. Rioli V., Gozzo F.C., Heimann A.S., Linardi A., Krieger J.E., Shida C.S., Almeida P.C., Hyslop S., Eberlin M.N., and Ferro E.S. Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme. J Biol Chem 278 (2003) 8547-8555
45. Sandkuhler J., Treier A.C., Liu X.G., and Ohnimus. The massive expression of c-fos protein in spinal dorsal horn neurons is not followed by long-term changes in spinal nociception. Neuroscience 73 (1996) 657-666
46. Santos R.A., Ferreira A.J., and Simoes E Silva A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol 93 (2008) 519-527
47. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-58
48. Shimamura M., Kawamuki K., and Hazato T. Angiotensin III: a potent inhibitor of enkephalin-degrading enzymes and an analgesic agent. J Neurochem 49 (1987) 536-540
49. Sim M.K. Degradation of angiotensin I in the endothelium and smooth muscle of the rat aorta. Biochem Pharmacol 45 (1993) 1524-1527
50. Sim M.K., Choo M.H., and Qiu X.S. Degradation of angiotensin I to (des-Asp1)-angiotensin I by a novel aminopeptidase in the rat hypothalamus. Biochem Pharmacol 48 (1994) 1043-1046
51. Song L., Wilk S., and Healy D.P. Aminopeptidase A antiserum inhibits intracerebroventricular angiotensin II-induced dipsogenic and pressor responses. Brain Res 744 (1997) 1-6
52. Song L., Ye M., Troyanovskaya M., Wilk E., Wilk S., and Healy D.P. Rat kidney glutamyl aminopeptidase (aminopeptidase A): molecular identity and cellular localization. Am J Physiol 267 (1994) F546-F557
53. Tieku S., and Hooper N.M. Inhibition of aminopeptidases N, A and W. A re-evaluation of the actions of bestatin and inhibitors of angiotensin converting enzyme. Biochem Pharmacol 44 (1992) 1725-1730
54. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., Lee R.J., Wexler R.R., Saye J.A., and Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45 (1993) 205-251
55. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., and Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 (2000) 33238-33245
56. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., and Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277 (2002) 14838-14843
57. Villarreal C.F., Kina V.A., and Prado W.A. Participation of brainstem nuclei in the pronociceptive effect of lesion or neural block of the anterior pretectal nucleus in a rat model of incision pain. Neuropharmacology 47 (2004) 117-127
58. von Bohlen und Halbach O., and Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 326 (2006) 599-616
59. Wilk S., and Healy D.P. Glutamyl aminopeptidase (aminopeptidase A), the BP-1/6C3 antigen. Adv Neuroimmunol 3 (1993) 195-207
60. Wilk S., Wilk E., and Magnusson P.P. Purification, characterization and cloning of a cytosolic aspartyl aminopeptidase. J Biol Chem 273 (1998) 15961-15970
61. Wilson W.L., Roques B.P., Speth R.C., Harding J.W., and Wright J.W. Roles of brain angiotensins II and III in thirst and sodium appetite. Llorens-Cortes. Brain Res 1060 (2005) 108-117
62. Wright J.W., and Harding J.W. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept 59 (1995) 269-295
63. Wright J.W., Morseth S.L., Abhold R.H., and Harding J.W. Pressor action and dipsogenicity induced by angiotensin II and III in rats. Am J Physiol 249 (1985) R514-R521
64. Wright J.W., Tamura-Myers E., Wilson W.L., Roques B.P., Llorens-Cortes C., Speth R.C., and Harding J.W. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am J Physiol Regul Integr Comp Physiol 284 (2003) R725-R733
65. Wright J.W., Yamamoto B.J., and Harding J.W. Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog Neurobiol 84 (2008) 157-181
66. Yaksh T.L., Yeung J.C., and Rudy T.A. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res 114 (1976) 83-103
67. Yang C.H., Shyr M.H., Tan P.P., and Chan S.H. Participation of AT1 and AT2 receptors in the differential interaction between angiotensin II or III and alpha-2 adrenoceptors in the nucleus reticularis gigantocellularis in cardiovascular regulation and antinociception in rats. J Pharmacol Exp Ther 279 (1996) 795-802
68. Yien H.W., Chan J.Y., Tsai H.F., Lee T.Y., and Chan S.H. Participation of nucleus reticularis gigantocellularis in the antinociceptive effect of angiotensin III in the rat. Neurosci Lett 159 (1993) 9-12
69. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110
70. Zini S., Fournie-Zaluski M.C., Chauvel E., Roques B.P., Corvol P., and Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A 93 (1996) 11968-11973